Although industry-funded continuing medical education (CME) has been much
maligned by medical journals, professional organizations, and legislators
recently, some advocates and prominent physicians believe that banning
industry funding would do more harm than good.
Currently, pharmaceutical and medical-device companies fund half of the $3
billion CME industry, and much of this money goes to for-profit medical
communication companies that organize CME programs and symposia
(Psychiatric News, April 4, April 18). This aspect of the
industry-medicine relationship is just one of many that has been criticized
for potential or existing conflicts of interests by voices outside and within
the medical profession, including Sen. Charles Grassley (R-Iowa), chair of the
Senate Special Committee on Aging, consumer-advocate groups, and some academic
physicians (Psychiatric News, August 15).
The AMA's Council on Ethical and Judicial Affairs, for example,
proposed eliminating all industry funding for professional education
activities earlier this year. Similarly, the Accreditation Council for
Continuing Medical Education (ACCME) recently invited public comments on a
proposed ban of industry funding for CME.
At a public meeting last month in Washington D.C., organized by the
nonprofit Center for Medicine in the Public Interest (CMPI), several notable
physicians and representatives of for-profit medical communication companies
strongly opposed the view that industry funding for CME is harmful to the
medical profession.
"The system works," said George Lundberg, M.D., editor-in-chief
of Medscape Journal and the eMedicine Web site. Medscape provides
online CME funded by pharmaceutical companies, with free access for health
care professionals. The current guideline for conflict-of-interest disclosure
by the ACCME is sufficient to prevent CME authors from presenting biased
information, he stated.
Lundberg was editor of the Journal of American Medical Association
(JAMA) from 1982 to 1999. He noted that the AMA cannot be entirely
free of ties with industry; for example, it was JAMA advertising
revenue that allowed AMA to charge no membership dues until 1948. Some
academics "simply feel ideologically that physicians have to pay for
their CME," he reflected. "We all have conflicts of interest,
overt or covert."
Lundberg disagreed with recent commentaries in JAMA on
conflict-of-interest issues. Arnold Relman, M.D., editor-in-chief emeritus of
the New England Journal of Medicine and a professor emeritus of
medicine and social medicine at Harvard Medical School, wrote in the September
3 issue that "the responsibility for medical education should be
entirely in the hands of the medical profession, and funding should not
compromise, or even call into question, the integrity and independence of what
is taught."
Other physicians who spoke at the meeting agreed with Lundberg's
sentiment. "Banning industry-funded CME is not justified and will have
unintended consequences, especially in primary care and psychiatry,"
said Roger Meyer, M.D., a clinical professor of psychiatry at Georgetown
University Medical School and president of the American College of
Neuropsychopharmacology in 1993. He is also a partner at Best Practice Project
Management Inc., a consulting company that works with drug companies.
Meyer pointed out that in academic medical centers, the departments of
primary care and psychiatry do not generate enough profit for themselves to
sustain the training necessary for residents and students, and centralized
institution-generated CME programs often cost the departments. Without
industry funding, these departments cannot afford to bring in distinguished
outside experts for their grand rounds.
Recently Pfizer became the first drug company to halt direct funding to
for-profit medical communication companies (Psychiatric News, August
1). Representatives from the CME industry, including Marissa Seligman,
Pharm.D., senior vice president of Pri-Med Institute, a large medical
communication company, reported at the meeting that industry funding for CME
has declined noticeably in recent months. The for-profit CME industry has
maintained that industry funding allows more effective, innovative, and widely
accessible educational programs, particularly for those with no academic
medical center affiliations or those with primary care practices in
underserved areas.
If industry funding dries up, either because of regulation or
industry's business decisions, physicians also will lose many of the
educational services provided by professional associations, suggested Jack
Lewin, M.D., chief executive officer of the American College of Cardiology
(ACC). Without industry grants, the ACC would have to charge $2,000 to $3,000
registration fees per attendee to maintain the same educational content and
services currently provided at annual meetings, he estimated.
If all industry support was banned, the ACC would certainly have to cut
member services or charge far higher member dues, Lewin told Psychiatric
News. By pooling industry funds, building a "firewall"
between the sponsors and CME content development, and scrutinizing potential
conflicts of interest of authors and faculties, CME can be free of bias.
"Transparency is beneficial," he said. "[Banning industry
support] will slow the dissemination of knowledge."
Robert Goldberg, Ph.D., vice president and cofounder of CMPI, told
Psychiatric News that the organization receives donations primarily
from pharmaceutical and biotechnology companies. Peter Pitts, president and
cofounder of CMPI, served as the associate commissioner for external relations
at the FDA from 2002 to 2004.
The meeting was cohosted by the Coalition for Healthcare Communication,
whose members are medical publishing, advertising, and marketing
organizations. ▪